Exelixis (EXEL) Stock

Investors focused on Medical - Biomedical and Genetics stocks may have come across Exelixis (EXEL) and Incyte (INCY). However, which of these two stocks is more appealing to value investors?

Exelixis (EXEL) is likely to do better than the market because it shows strong financial growth.

Investors looking at Medical - Biomedical and Genetics stocks probably know about Exelixis (EXEL) and Incyte (INCY). However, which of these two stocks is more appealing for value investors?

In 2024, the biotech sector has not performed as well as the overall market. The SPDR S&P Biotech ETF, which is a key measure for the industry, has increased by 9% this year, while the S&P 500 has risen by 28%. However, both CRISPR Therapeutics and Exelixis still have promising futures despite the different trends.

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.

Exelixis (EXEL) shared its earnings report 30 days ago. What can we expect for the stock moving forward?

The FDA informed EXEL that its supplemental New Drug Application (sNDA) for expanding the label of cabozantinib will be reviewed at an ODAC meeting scheduled for March 2025.

EXEL's stock has increased by 25% in a month due to impressive third-quarter results and an improved forecast. We feel positive about the stock because we think it has potential for further growth.

Exelixis (EXEL) is likely to do better than the market because it shows strong financial growth.